奥卡西平与丙戊酸钠对癫痫患者血液学指标、认识功能及生活质量的影响

Effect of Oxcarbazepine and Sodium Valproate on Hematological Indexes,Cognitive Function and Quality of Life in Patients with Epilepsy

目的:探讨奥卡西平与丙戊酸钠对癫痫患者血液学指标、认识功能及生活质量的影响。方法:将2015年6月至2017年5月我院接诊的癫痫患者98例纳入本研究,随机分为观察组(n=49)和对照组(n=49),对照组给予丙戊酸钠治疗。观察组给予奥卡西平治疗。比较两组同型半胱氨酸(Hcy)、不对称二甲基精氨酸(ADMA)水平、简明精神状态检查量表(MMSE)评分、癫痫患者生活质量量表(QOLIE)评分,并比较两组不良反应发生情况。结果:治疗后两组患者Hcy、ADMA水平均高于治疗前,差异有统计学意义(P<0.05),但治疗前和治疗后两组患者Hcy、ADMA水平组间比较差异均无统计学意义(P>0.05)。观察组治疗后MMSE评分高于治疗前和对照组(P<0.05);对照组治疗前后MMSE评分对比,差异无统计学意义(P>0.05)。两组患者治疗后QOLIE各项评分高于治疗前(P<0.05),观察组治疗后精力/疲乏、认知功能、药物影响等评分以及总评分高于对照组(P<0.05)。观察组不良反应发生率为4.08%,与对照组的10.20%比较差异无统计学意义(P>0.05)。结论:奥卡西平与丙戊酸钠治疗癫痫患者均可升高其Hcy、ADMA水平,无严重不良反应发生,而奥卡西平在改善癫痫患者的认知功能和生活质量等方面优于丙戊酸钠。

Objective: To explore effect of oxcarbazepine and sodium valproate on hematological indexes, cognitive function and quality of life in patients with epilepsy. Methods: 98 patients with epilepsy who were received in our hospital from June 2015 to May 2017 were included in this study, and they were randomly divided into the observation group (n=49) and the control group (n=49), the control group were treated with sodium valproate, the observation group were treated with oxcarbazepine. The levels of homocysteine (Hcy), asymmetric dimethlarginine (ADMA), mini-mental state examination (MMSE) score, and quality of life in epilepsy (QOLIE) score in two groups were compared. The incidence of adverse reactions in two groups was compared. Results: After treatment, the levels of Hcy and ADMA in the two groups were higher than those before treatment, and the difference was statistically significant (P<0.05), but there was no significant difference in Hcy and ADMA between the two groups before and after treatment (P>0.05). After treatment, the MMSE scores of the observation group was higher than that before treatment and the control group (P<0.05), and there was no significant difference in MMSE scores before and after treatment in the control group (P>0.05). The various scores of QOLIE of patients in two groups after treatment was higher than that before treatment (P<0.05), the scores of energy/fatigue, cognitive function, the influence of drugs and total scores of the observation group after treatment were higher than in control group (P<0.05). The incidence of adverse reactions in the observation group was 4.08%, and there was no statistically significant difference compared with 10.20% of the control group (P>0.05). Conclusion: Oxcarbazepine and sodium valproate can increase the levels of Hcy, ADMA in patients with epilepsy, and there is no serious adverse reactions, but oxcarbazepin is better than that of sodium valproate in improving cognitive function and quality of life in patients with epilepsy.